Pimm M V, Gribben S J
Cancer Research Laboratories, University of Nottingham, UK.
Life Sci. 1995 Mar 17;56(17):1401-6. doi: 10.1016/0024-3205(95)00104-2.
The feasibility of using immobilised anti-combining site (anti-idiotypic) antibodies as targets for assessing the immunoreactivity of radiolabelled anti-tumour monoclonal antibodies has been assessed. With two anti-tumour monoclonal antibodies (anti-CEA and anti-gp72) it was possible to quantify binding of their 125I labelled Fab fragment preparations to their anti-idiotypic monoclonal antibodies immobilised on cyanogen bromide activated Sepharose. Binding was specific for immobilised anti-idiotypic antibodies reactive with the anti-tumour antibody fragments. Moreover binding was inhibited by unlabelled Fab or intact monoclonal antibody, but not by an irrelevant antibody or its Fab fragment. The use of anti-idiotypic antibodies for quantifying immunoreactions of radiolabelled antibodies has advantages over the use of initial target antigen, which may be available only in inconvenient forms, such as cultured tumour cells.
已评估了使用固定化抗结合位点（抗独特型）抗体作为评估放射性标记抗肿瘤单克隆抗体免疫反应性的靶点的可行性。使用两种抗肿瘤单克隆抗体（抗癌胚抗原和抗gp72），可以定量其125I标记的Fab片段制剂与固定在溴化氰活化琼脂糖上的抗独特型单克隆抗体的结合。结合对于与抗肿瘤抗体片段反应的固定化抗独特型抗体具有特异性。此外，未标记的Fab或完整单克隆抗体可抑制结合，但无关抗体或其Fab片段则不能。与使用初始靶抗原相比，使用抗独特型抗体定量放射性标记抗体的免疫反应具有优势，因为初始靶抗原可能仅以不方便的形式获得，例如培养的肿瘤细胞。
